Pressmeddelande

Mangold Insight publishes interview with Biosergen’s CEO

Cision Publicerad: 26 Sep 2022 08:52

Mangold Insight have published an interview with Peder Andersen, CEO of Biosergen. The interview expands upon, among other things, the following questions:

What can you tell us about Biosergens main candidate BSG005?
Can you tell us about the competitors and market opportunities for BSG005?
What will the proceeds from the rights issue be used for?

Click here to see the full interview.

Shareholder letter available on website
For information on how to subscribe in the Rights Issue and a few summarizing words from CEO Peder Andersen, see the shareholder letter published on www.biosergen.net or https://emission.mangold.se/.

Advisers
Mangold Fondkommission AB is the financial adviser to Biosergen in connection with the Rights Issue. Advokatfirman Lindahl KB is the legal adviser to the Company in connection with the Rights Issue.

Bifogade filer

Releasehttps://mb.cision.com/Main/20568/3636334/1630746.pdf

Nyheter om Biosergen

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!